HCPLive

Lawrence Brandt, MD, on Fecal Microbiota Transplant Study, Part I

$shareThis$
Lawrence Brandt, MD, professor of medicine and surgery at the Albert Einstein College of Medicine in New York City, discusses a study on the outcomes of fecal microbiota transplants on almost 100 patients across the country with refractory Clostridium difficile colitis. He explains that 91 percent of the patients experienced prompt relief. Including those who underwent a second transplant or a post-transplant course of medication, 98.3 percent of the patients experienced relief. This video was shot at the annual scientific conference of the American College of Gastroenterology.

Most Popular

Recommended Reading

Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.
As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.
Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.
$vacMongoViewPlus$ $vAR$